Rossari Biotech Limited Earnings Summary — Q3 FY2025
Rossari Biotech Reports 10.6% Consolidated Revenue Growth and Net Profit of ₹317 Million
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 3 consecutive quarters.
- Revenue of ₹697 Cr is 28.2% higher year-on-year.
- Revenue has compounded at 18.9% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit of ₹35 Cr is 4.5% above the same quarter last year.
- Profit growth is trailing revenue growth this quarter.
- Net profit has compounded at 1.3% annualised across the period.
- Operating margin stands at 11.6% in Q1 FY2027.
- Operating margin compressed by 92 bps year-on-year.
- Over the last two years operating margin has contracted by 169 bps.
- PBT margin is 6.8%.
- Expenses grew 29.6% against revenue growth of 28.2%.
- Operating profit of ₹81 Cr is 18.8% higher year-on-year.
- Operating leverage continues to improve.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 64/100 (Healthy) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 697 | 685 | 582 | 586 | 544 | 580 | 513 | 498 | 490 | 473 |
| Expenses | Improving | 617 | 608 | 513 | 514 | 476 | 510 | 448 | 432 | 425 | 409 |
| Operating Profit | Stable | 81 | 77 | 69 | 72 | 68 | 69 | 65 | 66 | 65 | 64 |
| Operating Margin | Stable | 11.6% | 11.3% | 11.8% | 12.3% | 12.5% | 12.0% | 12.6% | 13.2% | 13.3% | 13.4% |
| Other Income | Volatile | 4 | 20 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| Interest | Strong Uptrend | 11 | 9 | 8 | 6 | 6 | 6 | 5 | 4 | 4 | 3 |
| Depreciation | Improving | 26 | 24 | 20 | 18 | 18 | 18 | 18 | 15 | 15 | 16 |
| Profit Before Tax | Stable | 48 | 64 | 43 | 50 | 46 | 48 | 42 | 48 | 47 | 46 |
| Tax | Improving | 13 | 18 | 10 | 13 | 13 | 13 | 11 | 13 | 12 | 11 |
| Net Profit | Stable | 35 | 46 | 33 | 37 | 34 | 34 | 32 | 35 | 35 | 34 |
| Net Margin | Softening | 5.0% | 6.7% | 5.6% | 6.3% | 6.2% | 5.9% | 6.2% | 7.1% | 7.1% | 7.2% |
Key Takeaways
- Consolidated revenue grew 10.6% YoY to ₹5,127.3 million, showing continued top-line scale.
- Profitability faced pressure with PAT declining 7.8% YoY and 10.3% QoQ, reflecting margin compression.
- Total expenses rose significantly, driven by a 22.8% YoY increase in employee benefit expenses and higher depreciation.
- The company expanded its global footprint by incorporating 'Rossari International' in Saudi Arabia and acquiring Unistar Thai Co. Ltd.
- Standalone results showed stronger sequential growth in revenue (+9.6%) and PAT (+11.7%) compared to consolidated performance.
- Board approved shifting the registered office to 'Rossari House' in Vikhroli, effective February 2025.
- The company continues to operate as a single segment under Specialty Chemicals, maintaining its diversified platform strategy.
Management Guidance
Management remains focused on the 'Rossari 2.0' strategy, aiming for premiumization and multi-segment cross-selling across Home, Personal Care, Textile, and Animal Health segments. Execution is centered on integrating recent acquisitions to drive long-term capital efficiency despite current margin moderation.
Sentiment Shift
Deteriorating
While revenue growth remains positive, the significant QoQ and YoY decline in net profit and narrowing margins signal a struggle to pass on costs or maintain pricing power amid expansion.
Outlook
The outlook is focused on global expansion into Middle Eastern and SE Asian markets. However, the company must stabilize its operating margins and improve return on equity, which has trended downwards following aggressive capital expenditure.
From the Annual Report (Key Quotes)
“The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.”
“During the quarter ended 31st December, 2024, the Company has incorporated a wholly owned subsidiary 'Rossari International Limited Company' in Kingdom of Saudi Arabia.”
“All equity shares allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Rossari Biotech Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.